Strategic Investments And Industry Consolidation Drive Growth In The Cell And Gene Therapy Market: A Key Driver Powering Cell and Gene Therapy Market Growth In 2025

The Cell and Gene Therapy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Cell and Gene Therapy Market Size and Its Estimated Growth Rate?
The market size for cell and gene therapy has seen a significant upsurge in the past few years. From a value of $12.01 billion in 2024, it's projected to expand to $15.48 billion in 2025, reflecting a compound annual growth rate (CAGR) of 28.9%. The historical growth pattern owes its progression to factors such as increased investment in cell and gene therapy, advancements in research and development, breakthroughs in the discovery of cancer drugs, growth of public-private partnerships, strong economic performance of emerging markets, escalated healthcare spending, and a rise in expenditure for pharmaceutical research and development.

Over the coming years, the cell and gene therapy market can expect a swift expansion. Projected to reach $29.15 billion by 2029 with a compound annual growth rate (CAGR) of 17.1%, this growth can be traced back to various factors. These include the growing instances of cancer and chronic illnesses, an increasing geriatric population, and a stronger focus on cell and gene therapies, coupled with a rise in healthcare spending. The outlook for this period also sees a focus on cutting-edge therapies like chimeric antigen receptor (CAR) T-cell therapy, high emphasis on research initiatives and sourcing funding, strategic collaborations for inculcating advanced technologies, efforts on gene or genome editing tools development, particularly CRISPR, acquisitions or partnerships with rival companies, a rise in the number of pipeline studies for developing cell and gene therapies, and substantial investments in expanding manufacturing facilities.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472

How Are Emerging Segments Shaping the Cell and Gene Therapy Market Landscape?
The cell and gene therapy market covered in this report is segmented -

1) By Product: Cell Therapy, Gene Therapy
2) By Application: Oncology, Neurological Disorders, Other Applications
3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:
1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy
2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

Which Growth Factors Are Influencing Cell and Gene Therapy Market Expansion?
The continuous influx of investments and consolidation in cell and gene therapies have been instrumental to the growth of the cell and gene therapy (CGT) market. Recognizing its potential, 16 of the top 20 biopharmaceutical companies, by revenue, integrated CGT products into their offerings. For example, in 2023, as stated by the BioIndustry Association (BIA), a UK-based institution representing the biotech and life sciences industry, over half the venture capital funding received by European enterprises were secured by UK cell and gene therapy companies. Typically, the UK accounts for approximately one-third of all European VC investments in life sciences, underpinning the robust standing of its cell and gene therapy sector. Consistent investment and consolidation in CGT production capacity resulted in an expanded production capacity, further driving the market growth. For instance, Purespring Therapeutics, a biotech firm based in the UK, obtained a funding of $105 million in October 2024. This fund support development of gene therapies for kidney diseases, including a phase 1/2 trial of an experimental treatment for immunoglobulin A nephropathy (IgAN). Purespring employs adeno-associated viruses (AAVs) for delivering its gene therapies into the body.

Who Are the Dominant Players Across Different Cell and Gene Therapy Market Segments?
Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

What Are the Latest Developing Trends in the Cell and Gene Therapy Market?
The cell and gene therapy (CGT) market is being molded by the advent of Chimeric antigen receptor (CAR) T-cell therapy. This particular treatment is a unique integration of cell and gene therapy where T cells are extracted from the patient's blood and then genetically modified to form distinctive receptors on their surface, referred to as chimeric antigen receptors (CARs). When these altered T cells, equipped with special receptors, are returned back into the patient, their modified receptors aid in identifying the surface antigen of the cancer cells, thereby leading to the eradication of tumor cells. For example, Bristol-Myers Squibb Company, a pharmaceutical company based in the US, gained approval for its CAR T cell therapy, named Breyanzi, from the United States Food and Drug Administration (US FDA) in June 2022. This therapy is for adult patients suffering from large B-cell lymphoma (LBCL), which includes diffuse large B-cell lymphoma. Breyanzi, created from a patient's own T cells, is a distinct CAR T cell therapy in which the cells are harvested and genetically altered to generate CAR T cells, then returned to the patient as a one-time treatment via infusion.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Which Geographic Regions Are Expected to Dominate the Cell and Gene Therapy Market in the Coming Years?
North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Cell and Gene Therapy Market?
2. What is the CAGR expected in the Cell and Gene Therapy Market?
3. What Are the Key Innovations Transforming the Cell and Gene Therapy Industry?
4. Which Region Is Leading the Cell and Gene Therapy Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.